Skip to main content

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Amedisys, Inc. (Nasdaq – AMED)

BALA CYNWYD, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Amedisys, Inc. (“Amedisys” or the “Company”) (Nasdaq – AMED) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Optum (“Optum”). Under the terms of the Agreement, Amedisys shareholders will only $101.00 per share in cash.

The investigation concerns whether the Amedisys Board breached its fiduciary duties to shareholders by failing to conduct a fair process resulting in Optum paying less than full value for the Company.

If you own shares of Amedisys stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, by email at, visiting, or calling tolling free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.